Nura Bio reports preclinical data validating a conserved mechanism of inhibition of NAD hydrolases implicated in neurodegeneration in NEURON Portfolio News / By Karina Tin September 13, 2022 Nura Bio reports preclinical data validating a conserved mechanism of inhibition of NAD hydrolases implicated in neurodegeneration in NEURON Read More »
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference Portfolio News / By Karina Tin September 13, 2022 NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference Read More »
Synthekine Named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022 Portfolio News / By Karina Tin September 12, 2022 Synthekine Named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022 Read More »
Tenaya Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301 Portfolio News / By Karina Tin September 6, 2022 Tenaya Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301 Read More »
Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022 Portfolio News / By Karina Tin September 6, 2022 Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022 Read More »
NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress Portfolio News / By Karina Tin September 6, 2022 NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress Read More »
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire Portfolio News / By Karina Tin September 1, 2022 Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire Read More »
ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update Portfolio News / By Karina Tin August 11, 2022 ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update Read More »
RAPT Therapeutics Reports Second Quarter 2022 Financial Results Portfolio News / By Karina Tin August 11, 2022 RAPT Therapeutics Reports Second Quarter 2022 Financial Results Read More »
Surrozen Reports Second Quarter 2022 Financial Results Portfolio News / By Karina Tin August 11, 2022 Surrozen Reports Second Quarter 2022 Financial Results Read More »
